Time‐integrated activity coefficient estimation for radionuclide therapy using PET and a pharmacokinetic model: A simulation study on the effect of sampling schedule and noise
Authors:
- 19 August 2016
- journal article
- research article
- Published by Wiley in Medical Physics
- Vol. 43 (9) , 5145-5154
Abstract
Purpose: The aim of this study was to investigate the accuracy of PET‐based treatment planning for predicting the time‐integrated activity coefficients (TIACs).Methods: The parameters of a physiologically based pharmacokinetic (PBPK) model were fitted to the biokinetic data of 15 patients to derive assumed true parameters and were used to construct true mathematical patient phantoms (MPPs). Biokinetics of 150 MBq 68Ga‐DOTATATE‐PET was simulated with different noise levels [fractional standard deviation (FSD) 10%, 1%, 0.1%, and 0.01%], and seven combinations of measurements at 30 min, 1 h, and 4 h p.i. PBPK model parameters were fitted to the simulated noisy PET data using population‐based Bayesian parameters to construct predicted MPPs. Therapy simulations were performed as 30 min infusion of 90Y‐DOTATATE of 3.3 GBq in both true and predicted MPPs. Prediction accuracy was then calculated as relative variability vorgan between TIACs from both MPPs.Results: Large variability values of one time‐point protocols [e.g., FSD = 1%, 240 min p.i., vkidneys = (9 ± 6)%, and vtumor = (27 ± 26)%] show inaccurate prediction. Accurate TIAC prediction of the kidneys was obtained for the case of two measurements (1 and 4 h p.i.), e.g., FSD = 1%, vkidneys = (7 ± 3)%, and vtumor = (22 ± 10)%, or three measurements, e.g., FSD = 1%, vkidneys = (7 ± 3)%, and vtumor = (22 ± 9)%.Conclusions: 68Ga‐DOTATATE‐PET measurements could possibly be used to predict the TIACs of 90Y‐DOTATATE when using a PBPK model and population‐based Bayesian parameters. The two time‐point measurement at 1 and 4 h p.i. with a noise up to FSD = 1% allows an accurate prediction of the TIACs in kidneys.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (GL 236/11-1, KL 2742/2-1)
- Bundesministerium für Forschung, Technologie und Raumfahrt (BMBF 02NUK008F)
- Direktorat Jenderal Pendidikan Tinggi (2644/E4.4/K/2013)
- Bundesamt für Strahlenschutz (BfS 3608S04001)
- Seventh Framework Programme (602306)
- Deutsche Forschungsgemeinschaft (DFG) (GL 236/11-1, KL 2742/2-1)
- Bundesministerium für Bildung und Forschung (BMBF) (BMBF 02NUK008F)
- Direktorat Jenderal Pendidikan Tinggi (DIKTI) (2644/E4.4/K/2013)
- Bundesamt für Strahlenschutz (BfS) (BfS 3608S04001)
- Seventh Framework Programme (FP7) (602306)
- Deutsche Forschungsgemeinschaft (GL 236/11-1, KL 2742/2-1)
- Bundesministerium für Forschung, Technologie und Raumfahrt (BMBF 02NUK008F)
- Direktorat Jenderal Pendidikan Tinggi (2644/E4.4/K/2013)
- Bundesamt für Strahlenschutz (BfS 3608S04001)
- Seventh Framework Programme (602306)
This publication has 41 references indexed in Scilit:
- Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapyMedical Physics, 2012
- Nuclear medicine dosimetry: Quantitative imaging and dose calculationsZeitschrift für Medizinische Physik, 2011
- 68Ga-DOTATATE PET/CT for the Early Prediction of Response to Somatostatin Receptor–Mediated Radionuclide Therapy in Patients with Well-Differentiated Neuroendocrine TumorsJournal of Nuclear Medicine, 2010
- In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide massNuclear Medicine and Biology, 2010
- Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic ModelJournal of Nuclear Medicine, 2010
- 177Lu‐[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategyCancer, 2010
- Physical aspects of scintigraphybased dosimetry for nuclear medicine therapyNuklearmedizin-Nuclear Medicine, 2010
- MIRD Pamphlet No. 21: A Generalized Schema for Radiopharmaceutical Dosimetry—Standardization of NomenclatureJournal of Nuclear Medicine, 2009
- DOTATOC: A powerful new tool for receptor-mediated radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997
- Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1997